Optomed Oyj

Optomed Oyj has a liquidity position that is relatively strong, with a current ratio of 2.39, indicating that the company has more than twice the current assets to cover its current liabilities. The company's cash and equivalents amount to EUR 9,909,000, which is a significant portion of its total assets of EUR 31,973,000. The price-to-book ratio of 1.38 suggests that the market value of the company is slightly higher than its book value, indicating a moderate level of investor confidence in the company's assets. In terms of profitability, Optomed Oyj is currently facing challenges, as evidenced by its negative operating income of EUR -6,041,000 and a net income of EUR -6,641,000. The return on equity (ROE) is at -27.65%, and the return on assets (ROA) is at -20.77%, both of which are significantly below the industry median for the Advanced Medical Equipment & Technology sector. The company's gross profit of EUR 10,874,000 is a positive sign, but it is not sufficient to offset the operating and net losses. The company's business is divided into two reportable segments: Devices and Software. The Devices segment is responsible for the development, commercialization, and manufacturing of handheld fundus cameras, while the Software segment focuses on the development and sale of screening software for diabetic retinopathy and cancer screening. The geographic exposure is not explicitly detailed in the provided data, but the company has subsidiaries in Finland, China, the USA, and Hong Kong, suggesting a diversified geographic presence. The growth trajectory of Optomed Oyj is currently constrained by its financial performance. The company's operating cash flow is negative at EUR -2,482,000, and its free cash flow is also negative at EUR -6,482,000. The capital expenditure of EUR -2,357,000 indicates that the company is investing in its operations, but the negative cash flows suggest that the company may need to rely on external financing to sustain its operations. The outlook for the current fiscal year is not explicitly provided, but the negative financial indicators suggest a challenging period ahead. The risk assessment for Optomed Oyj indicates a low level of liquidity and dilution risk. The company's debt-to-equity ratio is 0.11, which is relatively low, suggesting that the company is not heavily leveraged. The absence of immediate filing-based liquidity or dilution flags is a positive sign, but the company's negative operating and net income could pose a risk to its financial stability in the long term. The dilution potential is also low, as the number of shares outstanding for both basic and diluted shares is the same, indicating no imminent threat of share dilution. Recent events related to Optomed Oyj include the publication of its financial snapshot, which provides a detailed overview of the company's financial position. The company's market price is EUR 1.542, and the market cap is EUR 33,046,995.21. Analysts have provided a range of price targets, with a mean of EUR 3.97 and a median of EUR 3.80, indicating a generally positive outlook despite the company's current financial challenges. The mean recommendation from analysts is 2.00, which is a "Hold" rating, suggesting that investors are cautious but not overly pessimistic about the company's prospects.